876461-31-3

Usage

Uses

Used in Pharmaceutical Industry:
Cyclohexanamine, 4-[4-(cyclopropylmethyl)-1-piperazinyl]-, transis used as a key component in the development of new medications due to its potential therapeutic properties. Its unique chemical structure allows for the exploration of its applications in treating various conditions, making it a valuable asset in pharmaceutical research and development.
Used in Research and Development:
In the field of research and development, Cyclohexanamine, 4-[4-(cyclopropylmethyl)-1-piperazinyl]-, transis utilized for its unique chemical structure, which may contribute to the discovery of novel therapeutic agents. Its potential applications in creating new medications for various conditions make it an important compound for scientific exploration and innovation.

InChI:InChI=1/C14H27N3/c15-13-3-5-14(6-4-13)17-9-7-16(8-10-17)11-12-1-2-12/h12-14H,1-11,15H2/t13-,14-

Upstream product

• 57184-25-5 1-cyclopropylmethylpiperazine 
• 149506-79-6 4-(dibenzylamino)cyclohexanone 
• 373608-42-5 1-(cyclopropylmethyl)piperazine dihydrochloride 
• 149506-81-0 trans-4-(dibenzylamino)cyclohexanol 
• 50910-54-8 trans-4-aminocyclohexanol hydrochloride 
• 373608-50-5 4-cyclopropylmethylpiperazine-1-carboxylic acid tert-butyl ester 
• 27489-62-9 trans-4-hydroxycyclohexylamine 
• 882660-40-4 C₁₆H₂₉N₃O 
• 17578-82-4 N-(2-oxocyclohexyl)acetamide 
• 755039-89-5 (trans)-N,N-dibenzyl-4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexanamine 

Downstream Products

• 1280665-32-8 7-[[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-N-[(trans)-4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexyl]-2,3-dihydrobenzofuran-4-carboxamide 
• 1280665-50-0 N-[(trans)-4-[4-(Cyclopropylmethyl)piperazin-1-yl]cyclohexyl]-7-[[(7S)-7-ethyl-8-isopropyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-2,3-dihydrobenzofuran-4-carboxamide 
• 882660-39-1 C₂₂H₃₄N₄O₂ 
• 755038-65-4 Volasertib 
• 882660-36-8 C₂₂H₃₂N₄O₄ 

Relevant academic research and scientific papers

CYCLIN-DEPENDENT KINASE INHIBITING COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS

This invention is in the area of cell cycle inhibiting compounds for the treatment of disorders involving abnormal cellular proliferation, and include selective CDK2 inhibitors for medical therapy and their pharmaceutically acceptable salts and compositions.

DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF

Dihydroperidinone derivatives, preparation process and pharmaceutical use thereof are disclosed. Specially, new dihydroperidinone derivatives represented by general formula (I), wherein each substituent of the general formula (I) is defined as in the description, their preparation process, pharmaceutical compositions comprising said derivatives and their use as therapeutical agents, especially as Plk kinase inhibitors are disclosed.

DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF

Dihydroperidinone derivatives, preparation process and pharmaceutical use thereof are disclosed. Specially, new dihydroperidinone derivatives represented by general formula (I), wherein each substituent of the general formula (I) is defined as in the description, their preparation process, pharmaceutical compositions comprising said derivatives and their use as therapeutical agents, especially as Plk kinase inhibitors are disclosed.

Process for manufacturing dihydropteridinones and intermediates thereof

The present invention relates to an improved process for manufacturing dihydropteridinones of general formula (12) as well as intermediates thereof, wherein the groups R1, R2, R3, R4, and R5 have the

COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION

The present invention relates to a pharmaceutical composition for the treatment of diseases which involve cell proliferation. The invention also relates to a method for the treatment of said diseases, comprising co-administration of a compound 1 of Formula (I) wherein the groups L, R1, R2, R3, R4 and R5 have the meanings given in the claims and specification, optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, and of an effective amount of an active compound 2 and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of a compound 1 of Formula (I) and of an effective amount of an active compound 2 and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES

The present invention relates to the use of a compound of general Formula (1), optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, for the preparation of a pharmaceutical composition for the treatment of diseases characterized by abnormal cell proliferation in a human or non-human mammalian body by inhibition of polo like kinases as mitotic regulators.

New pteridinones as PLK inhibitors

Disclosed compounds of general formula (1) wherein L, Q1, Q2, X, Y, Ra, Rb, Rc, R1, R2, R3 and R4 are defined as in claim 1, which are suitable for the trea

PTERIDINONES USED AS PLK (POLO LIKE KINASE) INHIBITORS

The invention relates to compounds of general formula (1), wherein L, Q1, Q2, X, Y, Ra, Rb, Rc, R1, R2, R3, and R4 are defined as indicated in claim 1. Said